Navigation Links
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Date:8/6/2009

THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that Vectibix((R)) (panitumumab), administered in combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly prolonged progression-free survival (PFS) compared with FOLFOX alone in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC).

"We believe that these data document an important advance for patients with metastatic colorectal cancer," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "These are the first prospective Phase 3 data to demonstrate the utility of KRAS mutational analysis as a predictive biomarker."

Overall, the adverse event profile was as anticipated for an anti-EGFR antibody in combination with oxaliplatin-based chemotherapy, including known events such as skin toxicity, hypomagnesemia and diarrhea.

Originally designed to compare the treatment effect in the overall population, the study was amended to analyze outcomes with respect to the presence or absence of activating mutations in KRAS in the tumor itself. Tumor KRAS status was ascertained in more than 90 percent of the 1,183 patients enrolled in the trial.

Importantly, in patients with tumors harboring activating KRAS mutations, PFS was significantly inferior in the Vectibix arm. These data confirm previous findings when oxaliplatin-based chemotherapy and an anti-EGFR antibody are combined.

"Our study underscores the importance of KRAS status in identifying the appropriate patient population to be treated with Vectibix, consistent with worldwide labeling," said Perlmutter. "Not only is the improvement in progress
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
2. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
3. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
4. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
5. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
6. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
10. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
11. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Organovo Holdings, Inc. (NYSE ... on delivering breakthrough 3D bioprinting technology, announced today ... Executive Officer, will present live at VirtualInvestorConferences.com on ... to join us for this Company update," said ... our commercial launch of the exVive3D Liver, Bioprinted ...
(Date:2/27/2015)... and JERUSALEM , Feb. ... company developing octreotide capsules, its lead product for the ... $70 million Series E financing round. Participants in the ... Ventures, and an undisclosed blue chip public investment fund, ... 7 Med Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... Feb. 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... 5,250,000 shares of its common stock at a price ... proceeds to Tandem from this offering are expected to ... and other estimated offering expenses payable by Tandem. All ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... 2012 Bionovo, Inc. (OTCQB: BNVI), a pharmaceutical company focused ... treatments for women,s health and cancer, announced today that ... that the Phase 3 trial of Menerba (MF101) could ... clinical safety and tolerability data. Menerba is Bionovo,s oral ...
... leaders of "America,s pastime," a free open-source screen-reading software company, ... Camp Abilities have in common? All have taken successful strides ... are blind or visually impaired, which is why they were ... by the American Foundation for the Blind (AFB). Chosen ...
Cached Medicine Technology:Bionovo's Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™ 2Bionovo's Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™ 3Bionovo's Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™ 4American Foundation for the Blind Announces 2012 Access Award Winners 2American Foundation for the Blind Announces 2012 Access Award Winners 3
(Date:2/28/2015)... February 28, 2015 In recent years Medical ... of practicing physicians as a way for them to expand ... regarding Cannabis as medicine. Since the FDA still lists Cannabis ... resources available to licensed physicians that can help guide ... Dr. Deborah Malka in Santa Cruz, CA is a ...
(Date:2/28/2015)... February 28, 2015 Gerald “Solutionman” Haman ... blocks or barriers to innovative thinking. “The #1 ... was lack of tools,” reports Haman, who created the ... 57% of people felt that they did not have ... tools and resources to stimulate innovation. , Solutionman’s monthly ...
(Date:2/28/2015)... The Classic Denture Center , located ... Throughout all of March patients can receive $25 ... service can help overall mouth health and give ... notice certain symptoms that suggest the denture teeth are ... , 1.    Pain, clicking, and popping in the joints, 2.    Pain ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation ... time limits. They stated that in many cases, missing an ... nullify it. Many a time, delays in making an injury ... BC law. As a result, experts at Jiwa Law Corporation ... a personal injury lawyer in order to know more about ...
(Date:2/28/2015)... February 28, 2015 For those people ... person, the Mesothelioma Applied Research Foundation (Meso ... Tuesday, March 3, starting at 9:30 AM. , The ... registration. The broadcast can be accessed through any browser ... . , The Symposium is a unique event that ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2
... cancer, the side effects of chemotherapy and other ... research based on nano- and microtechnology from Tel ... as more effective cancer treatment. , New drug ... Tel Aviv University,s Department of Biochemistry allows drugs ...
... Feb. 19 A new analysis from the JUPITER ... in San Diego, California describes details of the stroke ... This data adds to the primary analysis of ... 20mg significantly reduced the risk of stroke by nearly ...
... Cholesterol-lowering statins, used by millions of Americans to ... problems, according to researchers at Texas Health Presbyterian ... and the influence of statin drugs," appears in ... physicians make quicker, more accurate diagnoses of suspected ...
... address the unmet and undiagnosed health needs of students ... communities , Alliance College -Ready Public School,s College-Ready ... Street, Los Angeles, 90015 will host a free school ... 11:00 a.m. to 3:00 p.m. Students and families attending ...
... marketing promotional products company, offers a specialty store filled with ... ... Lewiston, ME (PRWEB) February 19, 2009 -- Crestline Custom ... that trades on its easy, customer-friendly ordering process, offers scores ...
... Mardil Inc., a cardiac medical device company with ... the appointment of Daniel A. Pelak to its board ... of cardiac medical devices will serve as a guiding ... its unique device from the development stage to human ...
Cached Medicine News:Health News:New 'bubble' targets only cancer cells 2Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 2Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 3Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 4Health News:Dallas Scientists Discover Statins May Falsely Indicate Thyroid Problems 2Health News:High Achieving Los Angeles Charter School to Hold Health Fair Offering Free Medical Screening, Treatment and Information to Students and Their Families 2Health News:Crestline is the Source for Great Green Giveaways 2Health News:Crestline is the Source for Great Green Giveaways 3Health News:Mardil Inc. Appoints Medical Device Veteran Daniel A. Pelak to Its Board of Directors 2
... site introduces the DiamondTome™ Skin Resurfacing ... unique DiamondTome™ Wands, an evolution in ... to smoother, more youthful skin. , ... the benefits of DiamondTome's™ innovative approach ...
... is a state-of-the-art hair reduction and ... specially designed for use within a ... features and economy in a single ... treatment of unwanted hair, photo rejuvenation ...
... Start or expand your aesthetic practice ... SR, the cost-effective system that's gentle, powerful ... seeking the exciting benefits of IPL Skin ... system promises to be an indispensable tool ...
Standard Lipo-tubing...
Medicine Products: